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In a cohort of 29584 residents of Linxian, China, followed from 1985 to 2001, we conducted a case–cohort study of the magnitude
of the association of Helicobacter pylori seropositivity with cancer risk in a random sample of 300 oesophageal squamous cell
carcinomas, 600 gastric cardia adenocarcinomas, all 363 diagnosed gastric non-cardia adenocarcinomas, and a random sample of the
entire cohort (N¼1050). Baseline serum was evaluated for IgG antibodies to whole-cell and CagA H. pylori antigens by enzyme-
linked immunosorbent assay. Risks of both gastric cardia and non-cardia cancers were increased in individuals exposed to H. pylori
(Hazard ratios (HRs) and 95% confidence intervals¼1.64; 1.26–2.14, and 1.60; 1.15–2.21, respectively), whereas risk of
oesophageal squamous cell cancer was not affected (1.17; 0.88–1.57). For both cardia and non-cardia cancers, HRs were higher in
younger individuals. With longer time between serum collection to cancer diagnosis, associations became stronger for cardia cancers
but weaker for non-cardia cancers. CagA positivity did not modify these associations. The associations between H. pylori exposure
and gastric cardia and non-cardia adenocarcinoma development were equally strong, in contrast to Western countries, perhaps due
to the absence of Barrett’s oesophagus and oesophageal adenocarcinomas in Linxian, making all cardia tumours of gastric origin,
rather than a mixture of gastric and oesophageal malignancies.
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Helicobacter pylori is an important risk factor for gastric non-
cardia adenocarcinoma (Nomura et al, 2005; Kamangar et al,
2006), but its association with gastric cardia adenocarcinoma
is less clear. A combined analysis of 12 prospective studies
(Helicobacter and Cancer Collaborative Group, 2001) showed an
overall null association between H. pylori and gastric cardia cancer
risk. However, significant geographic variation may exist: most
East-Asian studies have shown an increased risk, whereas most
Western studies have shown either a null association or reduced
risk (Dawsey et al, 2002). For both cardia and non-cardia cancers,
the risk estimates may also be a function of study design and
length of follow-up (Helicobacter and Cancer Collaborative Group,
2001), age at diagnosis (Kato et al, 2004), and H. pylori strain
(Blaser et al, 1995).
Very few studies have examined the association between
H. pylori infection and oesophageal squamous cell carcinoma.
The results of these studies have been inconsistent, and both
positive (Ye et al, 2004) and inverse associations (Siman et al,
2001; Wu et al, 2005) have been reported.
People of Linxian, China, have very high rates of oesophageal
squamous cell carcinoma and gastric cardia adenocarcinoma, and
also moderately high rates of gastric non-cardia adenocarcinoma;
approximately 20% of residents die of these cancers. We
conducted this long-term prospective case–cohort study to
estimate the magnitude of the association of H. pylori seroposi-
tivity and risk of these cancers in Linxian, and to examine these
associations by time from serum collection to cancer diagnosis,
age, and CagA positivity.
MATERIALS AND METHODS
Study cohort
Subjects were selected from the cohort of all participants in the
Linxian General Population Trial, which is described elsewhere
(Blot et al, 1993; Li et al, 1993). In brief, the participants were
29584 healthy adults aged 40–69 years from four Linxian
communes. In the spring of 1985, 1 year before the start of
intervention, each participant was interviewed, given a brief
physical examination, and had 10ml of blood drawn. After
collection, serum specimens were separated, aliquoted, and stored
frozen at  701C for future analyses. All participants were
randomly assigned to one of eight vitamin/mineral combinations,
and the supplements were distributed from March 1986 to May
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y1991. Throughout the trial period, local health care providers
recorded cancer incidence and mortality data at monthly intervals.
Periodic surveys were conducted to verify completeness and
accuracy of the medical information. Pathology slides and/or
X-rays were available for 85% of the cancer cases in this study, and
these were reviewed by a panel of American and Chinese experts.
For cancer cases without such diagnostic materials and for deaths
due to causes other than cancer, reviews were performed by senior
Chinese experts. In the subsequent 10 years post-trial, subjects
were contacted monthly, either by village health workers or by
study interviewers, and cancer diagnoses were verified by senior
Chinese diagnosticians from Beijing. Case ascertainment is
considered complete and loss to follow-up minimal (n¼176 or
o1%). Outcomes for the present study were based on follow-up
data through May 2001.
For anatomic localisation of gastric tumours, cancers were
defined as cardia cancers if they were in the most proximal 3cm of
the stomach, and non-cardia cancers if they were distal to this
region (Blot et al, 1993; Li et al, 1993). Ninety-five percent
of anatomic localisations were made using endoscopy, surgery,
and/or X-rays.
The trial was approved by the institutional review boards of the
Cancer Institute of Chinese Academy of Medical Sciences and the
US National Cancer Institute.
Cases and subcohort
By March 2001, 1958 cases of oesophageal squamous cell
carcinoma, 1089 cases of gastric cardia adenocarcinoma, and 363
cases of gastric non-cardia adenocarcinoma were diagnosed. There
were no cases of oesophageal adenocarcinoma. For the H. pylori
assays, we used a case–cohort design, selecting a random sample
of 300 oesophageal cancers, 600 cardia cancers, and all 363 non-
cardia cancers as case subjects. For the comparison group, we
selected a random sample of 1050 subjects from the entire baseline
cohort, hereafter called the subcohort. Some of the subcohort
subsequently developed cancer, and these were added to the case
group from the date of diagnosis (and correspondingly removed
from this date from the subcohort). Serum samples were available
for 2138 (95%) of subjects. The final numbers were 335
oesophageal cancer cases (271 selected cases and 64 subcohort
cases), 582 cardia cancer cases (549 selected cases and 33
subcohort cases), 343 non-cardia cancer cases (326 selected cases
and 17 subcohort cases), and 992 subcohort members (with or
without one of these cancers).
Serologic assays
Serum was evaluated for IgG antibodies to whole-cell (WC) and
CagA H. pylori antigens by enzyme-linked immunosorbent assay,
as described previously (Limburg et al, 2001). Similar to previous
studies (Limburg et al, 2001), seropositivity cutpoints were defined
as optical density ratios X1.0 for WC antibodies and X0.35 for
CagA antibodies. Individuals who were negative for both
antibodies (WC , CagA ) were classified as H. pylori seronega-
tive, whereas individuals who were seropositive for either WC or
CagA antibodies were classified as H. pylori seropositive. This
classification system was selected because culture-based studies
have shown that individuals who are negative for H. pylori WC
antibodies but positive for CagA antibodies are true positives
(Romero-Gallo et al, 2002). Seropositive individuals were further
classified as carrying CagA-negative strains (WCþ, CagA )o r
CagA-positive strains (WCþ or WC , CagAþ) (Romero-Gallo
et al, 2002).
Experienced technicians who were unaware of subjects’ case–
control status performed the serologic assays in duplicate. When
two assayed aliquots provided indeterminate results (i.e., the
values straddled the seropositivity threshold), additional aliquots
were analysed and the average of all results (excluding obvious
outliers) was used to determine serologic status. One hundred and
twelve external quality control serum samples, aliquoted from a
single large pooled serum sample from Linxian, were equally
distributed among 56 different batches. On the basis of these
samples, the coefficients of variation were 15 and 20% for the WC
and CagA assays, respectively.
Statistical methods
Consistent with previous studies of upper gastrointestinal cancers
in Linxian, we considered age (years), sex (male vs female), history
of smoking and alcohol consumption (yes vs no), and body mass
index (kgm
 2) as potential confounders. Mean and standard
deviation of continuous variables (age and body mass index), and
numbers and percentages of categorical variables (sex, history of
smoking and alcohol consumption) were calculated and reported
for the subcohort and each cancer type.
We used Cox proportional hazards models to estimate the crude
and adjusted hazard ratios (HRs) and 95% confidence intervals
(95% CIs) for the associations with H. pylori, using special R-
software (Mark and Katki, 2006). As potential confounders made
no material difference in the estimated HRs, models were only
adjusted for age and sex. Hazard ratios were calculated for each
cancer, and also by time from serum collection to diagnosis (p5,
5.1–10, and 410 years), age group (p55 and 455 years at study
entry), and H. pylori strain (CagA-positive vs CagA-negative). The
assumption of proportional hazards was explored by calculating
HRs in three strata of time from serum collection to diagnosis
(p5, 5.1–10, and 410 years). These hazards changed significantly
over time for cardia and noncardia cancers, and were therefore
reported separately for each time period. All analyses were
repeated using logistic regression models and similar results were
obtained (data not shown). Throughout the paper, all P-values are
two-sided and P-values p0.05 were considered as significant.
RESULTS
Of the 992 subcohort members, 487 (49%) were positive for
antibodies to both H. pylori WC and CagA antigens, 175 (18%) for
only WC antibodies, 65 (7%) for only CagA antibodies, and 265
(27%) for neither. Thus, 73% of the subcohort members had
serologic evidence of H. pylori exposure.
Table 1 shows the demographic characteristics and potential
confounders in cancer cases and subcohort members. Compared
to the subcohort, all subgroups of cancer cases were older, and
cardia and non-cardia cancer cases had a higher proportion of
males. Prevalence of tobacco smoking, alcohol drinking, and mean
body mass index were similar among all subgroups (Table 1), and
their frequency by case status similar to those for the whole cohort
(Tran et al, 2005).
In all, 73% of the subcohort, 76% of oesophageal, 81% of cardia,
and 80% of the non-cardia cancer cases were positive for serum
H. pylori antibodies (Table 2). Adjusted HRs (95% CI) were 1.17
(0.88–1.57) for oesophageal, 1.64 (1.26–2.14) for cardia, and 1.60
(1.15–2.21) for non-cardia cancers.
Oesophageal cancer risk estimates did not show a clear trend
with time from serum collection, and none was significant
(Table 3), HRs (95% CIs) being 1.43 (0.90–2.29), 0.78 (0.50–
1.20), and 1.21 (0.74–1.96) for cases diagnosed p5, 5.1–10, and
410 years after serum collection, respectively (Table 3). The
association between H. pylori and gastric cardia cancer was
stronger in cases diagnosed 410 years after serum collection
than earlier: HRs (95% CIs) were 1.30 (0.92–1.85), 1.35 (0.93–1.97),
and 2.41 (1.50–3.88) for cardia cancer cases diagnosed in the
corresponding periods (Table 3). For non-cardia cancer, the risk
estimates declined after the first 5 years of follow-up, being 2.32
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y(1.35–3.97), 1.23 (0.77–1.98) and 1.27 (0.78–2.08), respectively
(Table 3).
Anti-H. pylori seropositivity was not a risk factor for
oesophageal squamous cell cancer in individuals p55 or those
455 years of age at diagnosis (Table 3). The associations between
serum antibodies to H. pylori and risk of both cardia and non-
cardia cancers were nonsignificantly stronger for individuals p55
years of age at diagnosis; HRs were close to 2.0 for those p55
years, but approximately 1.4 for those 455 at diagnosis (Table 3).
Table 4 shows the crude and adjusted HRs (95% CIs) for the
associations between CagA-negative and CagA-positive strains of
H. pylori and each cancer type. For oesophageal cancer, the HR
point estimates were less strong for CagA-positive than CagA-
negative strains (adjusted HR 1.08 and 1.43, respectively). For
cardia cancers, the adjusted HRs were slightly stronger for CagA-
positive than CagA-negative strains (1.75 and 1.35, respectively),
although their difference was not statistically significant. For non-
cardia cancers, the HR point estimates were similar (E1.60) for
CagA-positive and CagA-negative strains.
DISCUSSION
This study showed a positive association (HR 1.6) between
H. pylori infection and risk of gastric non-cardia cancer in
Linxian, lower than the average found in meta-analyses either from
international data (RR 3) (Huang et al, 1998; Eslick et al, 1999;
Helicobacter and Cancer Collaborative Group, 2001) or from
Chinese studies alone (RR 3) (Xue et al, 2001). The smaller risk
observed in Linxian may reflect the unusual predominance of
other risk factors in this population. Nutritional deficiency is
common in Linxian, and supplementation with a combination of
selenium, vitamin E, and beta-carotene has been shown to reduce
the risk of gastric cancer mortality in this area (Blot et al, 1993).
Table 1 Demographic characteristics, tobacco use, and alcohol consumption among cases and the subcohort
Subcohort (n¼992) ESCC (n¼335) GCA (n¼582) GNCA (n¼343)
Mean age in years(s.d.) 51.9 (8.9) 54.5 (8.5) 55.5 (7.7) 56.0 (7.9)
Number of males (%) 449 (45.3) 155 (46.3) 351 (60.3) 228 (66.5)
Number of male smokers (%)
a 329 (73.6) 111 (71.6) 237 (68.1) 161 (70.6)
Number of alcohol consumers (%)
a 239 (24.1) 68 (20.3) 138 (23.4) 81 (23.6)
Body mass index (kgm
 2) (s.d.) 22.0 (2.5) 21.5 (2.4) 21.8 (2.3) 21.5 (2.2)
aSmoking and drinking were both categorized as binary variables. Smoking in this population was almost entirely limited to male subjects, so the numbers and percents were
calculated only for men. Male subjects who ever smoked cigarettes for six or more months were classified as smokers; subjects who drank any alcoholic beverage in the last 12
months were classified as alcohol consumers.
Table 2 Hazard ratios associated with anti-H. pylori seropositivity by anatomic subsite
Number tested Number positive (%) Crude HR (95% CI) Adjusted HR
a (95% CI)
Subcohort 992 727 (73) — —
Oesophageal squamous cell cancer 335 254 (76) 1.16 (0.88–1.55) 1.17 (0.88–1.57)
Gastric cardia cancer 582 473 (81) 1.59 (1.24–2.05) 1.64 (1.26–2.14)
Gastric non-cardia cancer 343 276 (80) 1.51 (1.12–2.05) 1.60 (1.15–2.21)
aModels were adjusted for age, age-squared, and sex.
Table 3 Hazard ratios associated with anti-H. pylori seropositivity by time to diagnosis and age
Site Time to diagnosis (years) Age Number tested Number positive (%) Adjusted HR
a (95% CI)
Subcohort — — 992 727 (73) —
Oesophageal squamous cell cancer p5 124 101 (81) 1.43 (0.90–2.29)
5.1–10 108 75 (69) 0.78 (0.50–1.20)
410 103 78 (76) 1.21 (0.74–1.96)
p55 166 129 (78) 1.29 (0.86–1.94)
455 169 125 (74) 1.10 (0.73–1.66)
Gastric cardia cancer
p5 216 171 (79) 1.30 (0.92–1.85)
5.1–10 199 158 (79) 1.35 (0.93–1.97)
410 167 144 (86) 2.41 (1.50–3.88)
p55 287 244 (85) 2.04 (1.38–3.01)
455 295 229 (78) 1.39 (0.96–2.01)
Gastric non-cardia cancer
p5 124 107 (86) 2.32 (1.35–3.97)
5.1–10 113 88 (78) 1.23 (0.77–1.98)
410 106 81 (76) 1.27 (0.78–2.08)
p55 151 128 (85) 2.06 (1.25–3.40)
455 192 148 (77) 1.36 (0.88–2.10)
aModels were adjusted for age, age-squared, and sex.
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yIf a large proportion of non-cardia cancers in Linxian are caused
by other factors, then the relative risk for the association with
H. pylori will be attenuated. A similar argument may explain the
stronger associations seen in younger individuals in this and
certain other studies (Nomura et al, 1991; Hansson et al, 1993);
older people may have other strong risk factors for non-cardia
cancer.
The weaker H. pylori association with non-cardia cancer cases
diagnosed more than 5 years after serum collection differed from
that in cardia cancer cases, and also from that in most other long-
term prospective studies (Helicobacter and Cancer Collaborative
Group, 2001).
CagA-positive strains of H. pylori may be associated with a
greater risk of gastric non-cardia cancer by further increasing the
turnover of the gastric epithelium (Hatakeyama, 2004). Some but
not all studies have found that CagA-positive strains of H. pylori
are associated with a higher risk of non-cardia adenocarcinoma
than CagA-negative strains, and a meta-analysis of these studies
found that the presence of CagA-positive strains increased this risk
by two-fold (Huang et al, 2003). In the current study, CagA-
positive strains were not associated with a further increased risk of
non-cardia cancer.
The strength of the association with H. pylori infection was
similar for gastric cardia (HR 1.6) as for non-cardia gastric cancer,
as in several other East-Asian studies, but unlike in Western
countries, where the association with cardia cancer is null or
inverse (Hansen et al, 1999; Kamangar et al, 2006). This may
reflect a different definition of cardia cancer in Western vs Eastern
countries (Dawsey et al, 2002). In Western countries, where
Barrett’s oesophagus and adenocarcinoma of the oesophagus are
common, cardia cancer most likely includes a mixture of gastric
cardia and oesophageal adenocarcinomas. The cardia of the
stomach is a very small area, and differentiating large adenocarci-
nomas arising in the gastric cardia from those arising in the lower
oesophagus or the body of the stomach is not always possible.
In Linxian, however, Barrett’s oesophagus and oesophageal
adenocarcinoma are very rare or non-existent, so cardia tumours
probably mainly arise in the proximal stomach. This is supported
by our clinical experience in this population, in which all small
asymptomatic adenocarcinomas discovered near the gastro-
esophageal junction were on the gastric side of this junction.
The studies of H. pylori and gastric cardia cancer reported from
Western countries and East Asia suggest overall that H. pylori is
probably a risk factor for adenocarcinomas in the proximal
stomach but is probably protective against those in the distal
oesophagus.
The point estimates for the association between H. pylori and
cardia cancer were stronger in younger individuals, for cases that
were diagnosed long after serum collection, and for CagA-positive
strains. We did not find an association between H. pylori and
oesophageal squamous cell cancer, irrespective of age, time from
serum collection to diagnosis, or CagA-positivity. H. pylori does
not live in the oesophagus, but H. pylori-induced gastric atrophy
and subsequently reduced gastric acidity may allow overgrowth of
bacteria, which produce nitrosamines and thereby increase
oesophageal cancer risk (Ye et al, 2004). Both decreased (Siman
et al, 2001; Wu et al, 2005) and increased (Ye et al, 2004) risks of
oesophageal squamous cell cancer associated with H. pylori have
been reported. A case–control study (128 cases) in Taiwan found
an inverse association (adjusted odds ratio¼0.51) (Wu et al,
2005), as did a Swedish prospective study (29 cases) (odds
ratio¼0.41) (Siman et al, 2001). In contrast, a population-based
Swedish case–control study (85 cases) found a significant two to
three fold increased risk associated with CagA-positive serotypes,
and no association with CagA-negative serotypes (Ye et al, 2004).
In our data, smoking and alcohol consumption had only a small
role in the aetiology of oesophageal squamous cell cancer. These
two exposures are major risk factors for oesophageal squamous
cell carcinoma in Western populations (Brown et al, 1994, 2001),
but play a much smaller role in such high-risk areas, such as
Linxian (Tran et al, 2005) or northeastern Iran (Cook-Mozaffari
et al, 1979; Islami et al, 2004).
The strengths of this study include its large sample size,
prospective design, long-term follow-up, availability of data on
tumour location, the presence of data on potential confounders,
and measurement of both WC and CagA antibodies. This is the
largest reported prospective study of H. pylori and risk of these
three cancers. Previous studies of H. pylori and cardia cancer have
only had 20–60 cases, and may have included some oesophageal
adenocarcinomas misclassified as cardia cancers.
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Table 4 Hazard ratios associated with Cag-positive and Cag-negative H. pylori
Site Hp status N (%) Crude HR (95% CI) Adjusted HR
a (95% CI)
Subcohort Negative 265 (27) — —
Cag-negative 175 (18) — —
Cag-positive 552 (56) — —
Oesophageal squamous cell cancer Negative 81 (24) — —
Cag-negative 76 (23) 1.49 (1.04–2.13) 1.43 (0.99–2.07)
Cag-positive 178 (53) 1.07 (0.79–1.43) 1.08 (0.80–1.47)
Gastric cardia cancer Negative 109 (19) — —
Cag-negative 100 (17) 1.43 (1.03–2.00) 1.35 (0.95–1.92)
Cag-positive 373 (64) 1.64 (1.27–2.13) 1.75 (1.32–2.30)
Gastric non-cardia cancer Negative 67 (20) — —
Cag-negative 74 (22) 1.73 (1.18–2.54) 1.62 (1.08–2.45)
Cag-positive 202 (59) 1.45 (1.06–1.98) 1.58 (1.13–2.22)
Due to rounding, some percentages do not add up to 100%.
aModels were adjusted for age, age-squared, and sex.
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